Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. Current Liabilities for the year ending December 31, 2023: USD 17.31 M

Biomm S.A. Current Liabilities is USD 17.31 M for the year ending December 31, 2023, a -0.63% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Biomm S.A. Current Liabilities for the year ending December 31, 2022 was USD 17.42 M, a 23.54% change year over year.
Biomm S.A. Current Liabilities for the year ending December 31, 2021 was USD 14.10 M, a 10.76% change year over year.
Biomm S.A. Current Liabilities for the year ending December 31, 2020 was USD 12.73 M, a -15.73% change year over year.
Biomm S.A. Current Liabilities for the year ending December 31, 2019 was USD 15.11 M, a 42.38% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years